| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.07B | -5.7% | -3.8% |
| Cost of Revenue | $1.88B | -8.0% | -6.1% |
| R&D Expense | $140.0M | -1.4% | +4.5% |
| SG&A Expense | $387.0M | -4.4% | +0.0% |
| Interest Expense | $99.0M | +17.9% | +13.8% |
| Pre-tax Income | $327.0M | +6.9% | -44.2% |
| Income Tax | $19.0M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.96B | +6.4% | +18.8% |
| Accounts Receivable | $2.37B | -6.4% | +0.5% |
| Inventory | $1.84B | -19.9% | -17.8% |
| Current Assets | $10.02B | +46.3% | +55.6% |
| Total Assets | $38.04B | +4.1% | +1.6% |
| Current Liabilities |
| -72.1% |
| -82.1% |
| Net Income | -$123.0M | -308.5% | -127.1% |
| EPS (Basic) | -$0.29 | -307.1% | -126.6% |
| EPS (Diluted) | -$0.29 | -307.1% | -126.9% |
| $5.00B |
| +3.1% |
| +77.2% |
| Long-term Debt | $7.05B | +32.4% | -1.7% |
| Total Liabilities | $14.70B | +12.7% | +14.8% |
| Stockholders' Equity | $22.89B | -0.7% | -5.4% |